Dimerix Limited has granted Amicus Therapeutics exclusive rights to commercialize its drug candidate DMX-200 in the U.S. for Focal Segmental Glomerulosclerosis (FSGS), a serious kidney disease that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results